Loading clinical trials...
Loading clinical trials...
A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients
Conditions
Interventions
Pembrolizumab
Paclitaxel
+1 more
Locations
2
United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
Providence Cancer Center
Portland, Oregon, United States
Start Date
February 23, 2016
Primary Completion Date
August 21, 2019
Completion Date
December 1, 2026
Last Updated
April 24, 2026
NCT06681064
NCT05005403
NCT06547840
NCT06649331
NCT07029399
NCT06134375
Lead Sponsor
Providence Health & Services
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions